Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359603 | 1.00 | GJB2 (0.52) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL12924474 | 1.00 | GJB2 (0.52) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL15948696 | 1.00 | GJB2 (0.52) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL19644571 | 1.00 | GJB2 (0.52) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL17976782 | 1.00 | GJB2 (0.52) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL14532055 | 0.96 | GJB2 (0.48) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL14440515 | 0.94 | GJB2 (0.47) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL14440517 | 0.94 | GJB2 (0.47) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL12898674 | 0.93 | GJB2 (0.54) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL14440521 | 0.92 | GJB2 (0.50) | GJB2TNFSSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638053-B1 | URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES | JANSSEN PRODUCTS LP (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9012428-B2 | Uracyl spirooxetane nucleoside phosphoramidates | JANSSEN PRODUCTS, LP (US) | 2015-04-21 | — | — | US | disclosed |
| US-9006209-B2 | Uracyl spirooxetane nucleoside phosphoramidates | JANSSEN PRODUCTS, LP (US) | 2015-04-14 | — | — | US | disclosed |
| US-8933052-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2638054-B1 | URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES | JANSSEN PRODUCTS LP (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR, AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20130244968-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | TIBOTEC BVBA (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130225520-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | TIBOTEC BVBA (BE) | 2013-08-29 | — | — | US | disclosed |
| US-20130217648-A1 | Uracyl Spirooxetane Nucleosides | MEDIVIR AB (SE) | 2013-08-22 | — | — | US | disclosed |
| US-8481510-B2 | Uracyl spirooxetane nucleosides | JANSSEN PRODUCTS, LP (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2511282-A1 | Uracyl Spirooxetane Nucleosides | Janssen Products, L.P. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8242085-B2 | Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| WO-2012062870-A1 | URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES | JANSSEN PRODUCTS, LP (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062869-A1 | URACYL SPIROOXETANE NUCLEOSIDE PHOSPHORAMIDATES | JANSSEN PRODUCTS, LP (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110002886-A1 | TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2010130726-A1 | URACYL SPIROOXETANE NUCLEOSIDES | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2008141079-A1 | TETRAHYDROFURO [3 4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244968-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | NUDT1, UMPS, NUDT14 | GJB2 4699/4885TNF 4587/4885SSTR1 1721/4885 |
| US-20130225520-A1 | Uracyl Spirooxetane Nucleoside Phosphoramidates | NUDT1, NUDT14, UMPS | GJB2 4693/4885TNF 4170/4885SSTR1 2931/4885 |
| US-20130217648-A1 | Uracyl Spirooxetane Nucleosides | PNP, NUDT1, UMPS | GJB2 4783/4885TNF 4520/4885SSTR1 877/4885 |
| US-20140066398-A1 | HCV POLYMERASE INHIBITORS | POLI, HAVCR2, EIF2AK2 | GJB2 4654/4885TNF 2935/4885SSTR1 4414/4885 |
| US-20120213735-A1 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | DPYD, TYMP, TYMS | GJB2 3977/4885TNF 4140/4885SSTR1 4452/4885 |
| US-20110002886-A1 | TETRAHYDROFURO [3,4-D] DIOXOLANE COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND CANCER | FDFT1, DHODH, DHPS | GJB2 4489/4885TNF 590/4885SSTR1 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.